cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1634Research ArticleКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯCLINICAL STUDIESПреимущества антагониста кальция – нифедипина ГИТС, при лечении артериальной гипертонииBenefits of a calcium antagonist, nifedipine GITS, in arterial hypertension treatmentМычкаВ. Б.MychkaV. B.Victoria-mychka@yandex.ruЧазоваИ. Е.ChazovaI. E.Victoria-mychka@yandex.ruИнститут клинической кардиологии им. А.Л. Мясникова ФГУ “Российский кардиологический научно-производственный комплекс”, г. МоскваA.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex. Moscow200820122008765659Copyright © Мычка В.Б., Чазова И.Е., 20082008Мычка В.Б., Чазова И.Е.Mychka V.B., Chazova I.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1634сердечно-сосудистые заболеванияантагонисты кальциянифедипин ГИТСэффективность и безопасностьcardiovascular diseasecalcium antagonistsnifedipine GITSeffectiveness and safetyReferencesBrown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72.Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72.Mancia G, Brown M, Castaigne A, et al. Outcomes with nifedipine GITS or coamilozide in hypertensive diabetics and non- diabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41: 431-6.Mancia G, Brown M, Castaigne A, et al. Outcomes with nifedipine GITS or coamilozide in hypertensive diabetics and non- diabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41: 431-6.Poole-Wilson PA, Lubsen J, Kirwan BA, et al. On behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849-57.Poole-Wilson PA, Lubsen J, Kirwan BA, et al. On behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849-57.Estasio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with non insulin dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52.Estasio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with non insulin dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52.Packer MO, Connor C, Ghali J, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. New Engl J Med 1996; 335: 1107-14.Packer MO, Connor C, Ghali J, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. New Engl J Med 1996; 335: 1107-14.Dahlof B, Sever PS, Poulter NR, et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.Dahlof B, Sever PS, Poulter NR, et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.Zannad F, Bernaud CM, Fau R. Double-blind randomized multicentre comparibeyond in patients with mild to moderate hypertension. J Hypertens 1999; 17: 137-46.Zannad F, Bernaud CM, Fau R. Double-blind randomized multicentre comparibeyond in patients with mild to moderate hypertension. J Hypertens 1999; 17: 137-46.Yamazaki T, Komuro I, Zou Y, et al. Efficient inhibition of the development of cardiac remodeling by a longacting calcium antagonist amlodipine. Hypertension 1998; 31: 32-8.Yamazaki T, Komuro I, Zou Y, et al. Efficient inhibition of the development of cardiac remodeling by a longacting calcium antagonist amlodipine. Hypertension 1998; 31: 32-8.Goyal RK. Hyperinsulinemia and insulin resistance in hyper- tension: differential effects of antihypertensive agents. Clin Exp Hypertens 1999; 21: 167-79.Goyal RK. Hyperinsulinemia and insulin resistance in hyper- tension: differential effects of antihypertensive agents. Clin Exp Hypertens 1999; 21: 167-79.
The authors declare that there are no conflicts of interest present.